Spotlight on…
Substandard & Counterfeit Medicines
-
A generic medicine is a legitimately-produced medicine that is an exact copy of the originator product and performs in exactly the same way. Generic medicines used in donor-funded treatment programmes and by MSF must meet quality standards to prove they are just as effective as the originator product. Health programmes around the world rely on these affordable copycat medicines.
-
A substandard medicine is a drug that does not meet quality standards – it may contain too much or too little of the active ingredient, may be contaminated, may be poorly packaged or fail to meet quality standards in other ways. These medicines may be legitimately-produced mistakes or may have been knowingly produced to a substandard level. Both originator and generic medicines can be found to be substandard, and the issue of substandard medicines is a neglected one that needs far more attention.
-
A fake medicine is deliberately and fraudulently mislabelled, giving false information on where it was made or by whom, so that people will think it is a legitimate medicine. Fake medicines are dangerous as they are unlikely to contain the active pharmaceutical ingredient needed to make the medicine effective, and may even contain harmful substances. These medicines present a serious threat for public health that needs to be appropriately addressed.
-
The term ‘counterfeit medicine’ is overly-broad and creates confusion because it conflates intellectual property issues with public health problems. Different organisations and countries use different definitions of the word, making it hard to know exactly which problem is being referred to when this term is used. Some definitions focus on broad intellectual property terms and so confuse legitimate generic medicines with dangerous fakes. For this reason, MSF believes the term counterfeit should not be used in relation to medicine and instead more accurate and precise terms such as ‘fake’ or ‘substandard’ should be used.
Putting and end to the confusion and protecting generics
10 articles related to "Substandard & Counterfeit Medicines"
-
Joint statement by MSF, HAI Africa & KELIN on the Kenya Anti-Counterfeit Act 2008 decision
Health activists welcome High Court judgment on anti-counterfeit law 20 April 2012 -- After three years of waiting, health activists today welcomed a decision by the High court that the...
Statements, Speeches, Letters – Last updated 20 April 2012
www.msfaccess.org/content/joint-statement-msf-hai-africa-kelin-kenya-anti-counterfeit-act-2008-decision -
Briefing Note: Time to Focus on Quality
Médecins Sans Frontières briefing note ahead of the February 2011 meeting of Working Group of WHO Member States on substandard/ spurious/ falsely-labelled/ falsified/ counterfeit medical...
Briefing – Last updated 01 February 2011
www.msfaccess.org/content/briefing-note-time-focus-quality -
'Counterfeit' confusion diverts action from drug quality
Both fake and substandard medicines threaten public health, and efforts to tackle them must put the focus on quality, says Leena Menghaney. Numerous policy initiatives claim to promote patient...
Web article – Last updated 04 April 2011
www.msfaccess.org/content/counterfeit-confusion-diverts-action-drug-quality -
The Counterfeit Confusion
Phony Definition of 'Counterfeit Medicines' Costs Lives From luxury handbags, to cigarettes and DVDs, the mushrooming trade in counterfeit goods – deliberately faked products –...
Web article – Last updated 08 October 2010
www.msfaccess.org/content/counterfeit-confusion -
WHA 2010: Counterfeit Medicinal Products
Watch the new animation above which explains the fatal confusion between legitimate generic medicines and illegal fakes. Introduction The forthcoming 63rd World Health Assembly (WHA) will discuss...
Statements, Speeches, Letters – Last updated 29 April 2010
www.msfaccess.org/content/wha-2010-counterfeit-medicinal-products -
MSF's Letter to the 63rd WHA Delegates
Each World Health Assembly delegate received a packet in advance of the 2010 WHA. Included were this letter along with three briefing documents covering: infant and young child nutrition; public health,...
Statements, Speeches, Letters – Last updated 22 April 2010
www.msfaccess.org/content/msfs-letter-63rd-wha-delegates -
World Health Assembly 2010
At this year's 63rd World Health Assembly, MSF prepared a package of information for each of the delegates covering three topics in depth: infant and young child nutrition, counterfeit medicinal...
Events & Presentations – Last updated 02 June 2010
www.msfaccess.org/content/world-health-assembly-2010 -
FATAL FLAWS: How Kenya's 2008 Anti-Counterfeit Act could endanger access to medicines
Key sections of the Anti-Counterfeit Act must be clarified or amended if Kenyan patients are to continue accessing quality medicines at affordable prices. Ambiguities in the definition of counterfeit...
Briefing – Last updated 08 March 2010
www.msfaccess.org/content/fatal-flaws-how-kenyas-2008-anti-counterfeit-act-could-endanger-access-medicines -
Putting Patients’ Safety First - MSF briefing paper on the quality of medicines
Like all other actors in the field of public health, Médecins Sans Frontières teams are faced with the problem of medicines that do not meet World Health Organization (WHO) standards for...
Briefing – Last updated 22 May 2009
www.msfaccess.org/content/putting-patients%E2%80%99-safety-first-msf-briefing-paper-quality-medicines -
Counterfeit, Substandard and Generic Drugs
Counterfeit, substandard and generic drugs: distinct definitions for distinctly different problems People often seem to confuse counterfeit, substandard and generic medicines – using the...
Web article – Last updated 01 April 2009
www.msfaccess.org/content/counterfeit-substandard-and-generic-drugs

